Intec Pharma To Sponsor Investigator Meeting For Pivotal Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients
11/10/2016 3:10:29 PM
JERUSALEM, November 9, 2016 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announces that the Company will be hosting an investigator meeting on November 11-12, 2016 in Barcelona.
The investigator meeting will bring together more than 200 leading Parkinson's disease clinicians, care providers and clinical research coordinators.
These leading clinicians represent current and prospective clinical trial sites in the pivotal, Phase III clinical trial of the Company's Accordion Pill Carbidopa/Levodopa (AP-CD/LD), the Accordance Study, for the treatment of the symptoms of Parkinson's disease (PD) in advanced PD patients.
The Accordance study is a multicenter, randomized, double-blind, double-dummy, parallel, active-controlled Phase III trial in the United States, Europe and Israel. The study is now expected to enroll approximately 328 participants by the fourth quarter of 2017.
"The upcoming investigator meeting has been received with strong interest and we appreciate attendees taking time from their busy schedules to take part in this important two day event. This is one of the official investigators meetings during the phase III study. This meeting is especially timely as it follows on a recent protocol amendment to the Accordance Study in which we reduced the number of subjects from 460 to 328 subjects, without altering the primary endpoint, study objectives or 90% powering of the study. We look forward to what we expect will be an exceptional event centered on advancing AP-CD/LD to the benefit of PD patients worldwide," stated Zeev Weiss, CEO of Intec Pharma.
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, currently in Phase III, Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and sleep maintenance, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel ulcers induced by Nonsteroidal Anti-Inflammatory Drugs. In addition, an Accordion Pill for cannabinoid therapies (AP-CBD/THC) will enter Phase I clinical trial in the first quarter of 2017.
comments powered by